We are live on ! Find out more
ETC

Exchange Traded Concepts Portfolio holdings

AUM $21.9B
1-Year Est. Return 68.6%
This Fund
S&P 500
This Quarter Est. Return
+8.73%
1 Year Est. Return
+68.6%
3 Year Est. Return
+158.93%
5 Year Est. Return
+186.62%
10 Year Est. Return
AUM
$3.88B
AUM Growth
+$136M
Cap. Flow
-$98.6M
Cap. Flow %
-2.54%
Top 10 Hldgs %
15.31%
Holding
1,480
New
256
Increased
503
Reduced
456
Closed
248

Sector Composition

Rank Sector Weight
1 Technology 24.25%
2 Energy 11.27%
3 Healthcare 9.69%
4 Communication Services 7.57%
5 Industrials 7.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NGM
801
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$296K 0.01%
186,232
+79,213
+74% +$117K
GNLX icon
802
Genelux
GNLX
$127M
$294K 0.01%
45,736
+39,535
+638% +$359K
RCUS icon
803
Arcus Biosciences
RCUS
$3.33B
$294K 0.01%
15,553
+8,737
+128% +$151K
HLI icon
804
Houlihan Lokey
HLI
$9.72B
$293K 0.01%
+2,289
New +$283K
TSCO icon
805
Tractor Supply
TSCO
$16.3B
$293K 0.01%
+5,600
New +$268K
EGP icon
806
EastGroup Properties
EGP
$11.2B
$293K 0.01%
1,630
+178
+12% +$32.1K
CMPX icon
807
Compass Therapeutics
CMPX
$349M
$291K 0.01%
146,874
+81,055
+123% +$140K
APLM icon
808
Apollomics
APLM
$38.4M
$291K 0.01%
3,876
+3,519
+986% +$265K
HLT icon
809
Hilton Worldwide
HLT
$72.4B
$291K 0.01%
1,362
+1,157
+564% +$228K
KYMR icon
810
Kymera Therapeutics
KYMR
$8.66B
$290K 0.01%
7,212
-147
-2% -$5.26K
RLAY icon
811
Relay Therapeutics
RLAY
$4B
$289K 0.01%
34,876
+19,914
+133% +$194K
FATE icon
812
Fate Therapeutics
FATE
$275M
$289K 0.01%
39,410
-24,315
-38% -$151K
PGEN icon
813
Precigen
PGEN
$1.94B
$289K 0.01%
199,255
+105,164
+112% +$151K
MOR
814
DELISTED
MorphoSys AG American Depositary Shares
MOR
$288K 0.01%
15,883
-1,554
-9% -$23K
MRUS
815
DELISTED
Merus
MRUS
$288K 0.01%
6,389
+636
+11% +$25.8K
LYEL icon
816
Lyell Immunopharma
LYEL
$318M
$288K 0.01%
6,447
+2,299
+55% +$98.4K
RVMD icon
817
Revolution Medicines
RVMD
$38.5B
$287K 0.01%
8,910
-2,372
-21% -$70.3K
CGEM icon
818
Cullinan Oncology
CGEM
$1.06B
$287K 0.01%
16,850
+2,774
+20% +$42.9K
XNCR icon
819
Xencor
XNCR
$1.45B
$286K 0.01%
12,934
+6,158
+91% +$133K
HCM icon
820
HUTCHMED
HCM
$1.96B
$285K 0.01%
16,981
+7,450
+78% +$113K
HAL icon
821
Halliburton
HAL
$26.1B
$285K 0.01%
7,230
+7,158
+9,942% +$256K
ACLX
822
DELISTED
Arcellx
ACLX
$285K 0.01%
4,096
-145
-3% -$9.2K
INBX
823
DELISTED
Inhibrx, Inc. Common Stock
INBX
$285K 0.01%
8,143
+1,438
+21% +$52.4K
NDAQ icon
824
Nasdaq
NDAQ
$53.4B
$284K 0.01%
4,504
+1,427
+46% +$82.6K
JANX icon
825
Janux Therapeutics
JANX
$912M
$284K 0.01%
7,544
-6,660
-47% -$145K

Similar funds

Exchange Traded Concepts's Q1 2024 Portfolio in Review

As of Q1 2024, Exchange Traded Concepts held 1,480 positions worth $3.88B, up 3.6% from $3.74B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

Exchange Traded Concepts's Q1 2024 filing shows 256 new, 503 increased, 456 reduced and 248 closed positions. Its largest new stake was JPMorgan Equity Premium Income ETF: 966,844 shares worth $55.9M. The largest sale was Vanguard Short-Term Bond ETF, an estimated $55.9M.

By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 24% a quarter earlier, followed by Energy and Healthcare.

  • Exchange Traded Concepts's largest Q1 2024 buy was JPMorgan Equity Premium Income ETF: 966,844 shares worth $55.9M.
  • Exchange Traded Concepts added most to Janus Henderson AAA CLO ETF in Q1 2024, an estimated $39.3M increase.
  • Exchange Traded Concepts's biggest Q1 2024 reduction was State Street Utilities Select Sector SPDR ETF, cutting an estimated $39.2M.
  • Exchange Traded Concepts fully exited Vanguard Short-Term Bond ETF in Q1 2024, selling an estimated $55.9M.
  • Exchange Traded Concepts's ten largest holdings make up 15% of its $3.88B portfolio in Q1 2024.
  • Exchange Traded Concepts opened 256 new positions and closed 248 in Q1 2024.
  • Exchange Traded Concepts's portfolio value rose 3.6% quarter-over-quarter to $3.88B.

Based on Exchange Traded Concepts's 13F filing for Q1 2024, filed 15 Apr 2024.